NasdaqHealth CareHealth Care ServicesS&P MidCap 400
$16.01
+0.14 (+0.88%)
Close of Nov 06, 2026 · end-of-day data
SHC 8-K filings in 2026
Every material Form 8-K Sotera Health filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sotera Health reported third-quarter 2026 net revenues of $324.9 million, up 4.4% from $311.3 million a year earlier, and net income of $58.4 million, or $0.20 per diluted share, compared with $48.4 million, or $0.17, in the prior-year quarter. The company reaffirmed its full-year 2026 constant currency revenue and Adjusted EBITDA growth outlook, which means shareholders see steady profit growth with no change to expectations.
Q3 2026 net revenues were $324.9 million, up 4.4% from $311.3 million in Q3 2025.
Q3 2026 Adjusted EPS was $0.29, up 12% from $0.26 per diluted share a year earlier.
Full-year 2026 outlook reaffirmed: net revenue growth of 5.25% to 6.75% and Adjusted EBITDA growth of 5.75% to 7.25%, both on a constant currency basis.
Net leverage ratio was 2.9x as of September 30, 2026, compared with 3.2x at December 31, 2025.
Sotera Health director James C. Neary resigned from the board as a Class I director, effective August 13, 2026, after notifying the board on August 11, 2026. The company says the resignation was not due to any disagreement over operations, policies or practices, and the board reduced its size to eleven directors.
James C. Neary resigned as a Class I director, effective August 13, 2026
Notice of resignation given to the board on August 11, 2026
Company states no disagreement with management on operations, policies or practices
Board size fixed at eleven directors as of the effective date
Sotera Health reported second-quarter 2026 net revenues of $321.4 million, up 9.2% from a year earlier, and net income of $54 million, or $0.19 per diluted share, compared with $8 million, or $0.03, in the second quarter of 2025. The company raised its full-year 2026 net revenue and Adjusted EBITDA outlook, which points to higher expected results for shareholders this year.
Q2 2026 net revenues rose 9.2% to $321.4 million; Adjusted EPS was $0.26, up 30%
Q2 2026 net income was $54 million, or $0.19 per diluted share, versus $8 million, or $0.03, a year earlier
Full-year 2026 net revenue outlook raised to $1.236 billion to $1.254 billion; Adjusted EBITDA outlook raised to $634 million to $643 million
Sotera Health Company and its subsidiaries signed Amendment No. 7 to its First Lien Credit Agreement on May 20, 2026, under which refinancing lenders will provide $1.42 billion in repriced term loans to Sotera Health Holdings, LLC. The amendment reduces the interest rate spread by 0.25% across the facility's term loans, which lowers the company's borrowing cost on that debt.
Repriced term loans total about $1.42 billion, provided by 2026 Refinancing Term Lenders under the amended credit agreement.
Interest margin is Adjusted Term SOFR plus 2.25%, with a 0.00% floor, and the spread on term loans is reduced by 0.25%.
Repriced loans amortize at 1.00% per year and mature on May 30, 2031.
A 1.00% soft call premium applies to certain repricing transactions completed within six months after the amendment's effective date.
Sotera Health reported first-quarter 2026 net revenues of $280.0 million, up 10.0% from a year earlier, and net income of $26.6 million, or $0.09 per diluted share, compared with a net loss of $13.3 million a year earlier. The company reaffirmed its 2026 outlook and said Alton Shader will become chief executive officer on May 26, 2026, succeeding Michael B. Petras, Jr., who becomes Executive Chairman.
Q1 2026 net revenues were $280.0 million, up 10.0% from $254.5 million in Q1 2025, or 6.5% on a constant currency basis.
Q1 2026 net income was $26.6 million, or $0.09 per diluted share, versus a net loss of $13.3 million, or $0.05 per share, in Q1 2025.
The 2026 outlook was reaffirmed, including net revenues of $1.233 billion to $1.251 billion and Adjusted EBITDA of $632 million to $641 million.
Alton Shader, currently CEO of Viant Medical, will become CEO effective May 26, 2026, with an annual base salary of $1,000,000; Petras becomes Executive Chairman.
Sotera Health appointed Kenneth D. Krause as a Class I director effective March 16, 2026, and he will serve on the Audit and Litigation Committees. Constantine S. Mihas resigned from the same board seat, effective the same day, after some stockholders lost the right to designate that many directors; the filing says the resignation was not due to a disagreement with the company.
Krause appointed by the Board on March 15, 2026, effective March 16, 2026
Mihas notified the Board on March 12, 2026 of his resignation as a Class I director, effective March 16, 2026
Resignation tied to a reduction in the number of directors certain stockholders may designate; no disagreement cited
Krause is Executive Vice President and CFO of Rollins, Inc. since September 2022 and was previously CFO of MSA Safety
Sotera Health reported full-year 2025 net revenues up 5.7% to $1.164 billion and net income of $78 million, or $0.27 per diluted share, compared with $44 million, or $0.16 per diluted share, in 2024. The company also gave initial 2026 guidance for net revenues of $1.233 billion to $1.251 billion and Adjusted EBITDA of $632 million to $641 million. General Counsel Alex Dimitrief retires March 31, 2026, will serve as an advisor on ethylene oxide litigation, and Erika Ostrowski becomes Senior Vice President and General Counsel effective April 1, 2026.
Fourth-quarter 2025 net revenues rose 4.6% to $303 million, and net income was $35 million, or $0.12 per diluted share, versus $12 million a year earlier.
Full-year 2025 Adjusted EBITDA increased 8.2% to $594 million, and Adjusted EPS was $0.86, up $0.16 per diluted share.
2026 outlook: net revenues of $1.233 billion to $1.251 billion and Adjusted EPS of $0.93 to $1.01.
Dimitrief's advisory agreement is expected to pay $22,500 per month for up to 12 months.
Sotera Health expanded its board from eleven to twelve directors and appointed Richard G. Kyle as a Class III director, effective immediately, on February 4, 2026. Kyle previously served as president and CEO of The Timken Company from May 2014 to September 2024, and the filing describes him as independent under Nasdaq rules. The change adds an experienced industrial executive to the board and is a governance update rather than a financial result.
Board increased from eleven to twelve directors; Richard G. Kyle appointed Class III director effective February 4, 2026
Kyle to serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee
Kyle was President and CEO of The Timken Company from May 2014 to September 2024
Kyle receives standard non-employee director pay, including an annual cash retainer and annual restricted stock unit grant
Sotera Health said preliminary full-year 2025 revenue is expected to surpass $1.16 billion, an increase of at least 5.5% year over year, within the guidance it gave with its third-quarter results. The figures are preliminary and remain subject to year-end closing procedures and audit, and the company will release full results and 2026 outlook on February 24, 2026.
Preliminary 2025 revenue expected to surpass $1.16 billion, up at least 5.5% year over year (5.0% on a constant-currency basis)
Revenue approximation is within the guidance given at the third-quarter 2025 earnings release
Figures are unaudited and subject to completion of year-end closing and audit
Full-year 2025 results and 2026 outlook scheduled for February 24, 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sotera Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →